SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Forest Labs for treating chronic obstructive pulmonary disease, the agency said.
The FDA announced the approval of Tudorza Pressair (aclidinium bromide) for the long-term maintenance of COPD-related narrowing of the airways in the lung, also known as bronchospasm. The drug is an inhaled dry powder used twice per day.
"COPD is a serious disease that gets worse over time," FDA Office of Drug Evaluation II director Curtis Rosebraugh said. "The availability of long-term maintenance drugs for COPD provides additional treatment options for the millions of people who suffer with this debilitating disease."